
Opinion|Videos|October 14, 2024
Novel Research Frontiers on the Management of FCS
Key Takeaways
- Gene therapies, antisense oligonucleotides, and RNA interference technologies are promising advancements for FCS treatment, focusing on triglyceride reduction and symptom management.
- Clinicians should engage in continuous education, attend conferences, and collaborate with specialists to integrate emerging therapies into practice.
Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.
Advertisement
Video content above is prompted by the following:
What other approaches have been tested or are in development for treating familial chylomicronemia syndrome (FCS)?
How can clinicians integrate emerging therapy advancements into their clinical practice for the management of FCS? What strategies should be adopted to stay updated with ongoing research and treatment options?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
APPs on the Frontline of AATD Management, With Sarah Tomashefski, MSN
2
Phase 3 Data Indicate Roflumilast Cream Benefit Extend to Youngest Atopic Dermatitis Patients
3
RAD 2026: Tralokinumab Improves Hand AD Outcomes, Outperforms Dupilumab in MAIC
4
What is the Most Contested Issue in Atopic Dermatitis Today? With Mona Shahriari, MD
5
























































